Sign In
Buy MRKR
$1.45
+0.0300 (+2.11%)
At Close: Jun 03, 2026
Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference
08:00am, Wednesday, 30'th Jul 2025
HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for t
HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive
Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies
08:00am, Monday, 19'th May 2025
Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025 Virtual event with Key Opinion Leaders to discuss cell therapy landsca
Marker Therapeutics to Present at Canaccord Genuity's Horizons in Oncology Conference
08:00am, Tuesday, 01'st Apr 2025
HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for
Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results
08:45am, Monday, 31'st Mar 2025
Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, inc
Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference
07:00am, Tuesday, 25'th Feb 2025
HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
Marker Therapeutics Announces $16.1 Million Private Placement
08:06am, Thursday, 19'th Dec 2024
Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T cells Strategic financing supports clinical
Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma
08:05am, Thursday, 19'th Dec 2024
APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete response (CR)
HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
Marker Therapeutics to Present at the 2024 Ladenburg Thalmann & Co. Virtual Oncology Innovators and Investors Symposium
08:30am, Tuesday, 10'th Dec 2024
HOUSTON, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
Marker Therapeutics to Present at the Citizens JMP Hematology and Oncology Summit
11:00am, Tuesday, 26'th Nov 2024
HOUSTON, Nov. 26, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for th
Marker Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Updates
04:30pm, Thursday, 14'th Nov 2024
Marker Therapeutics to receive two grants from NIH Small Business Innovation Research (SBIR) program to support clinical investigation of MT-601 in patients with lymphoma and metastatic pancreatic can
Marker Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Updates
04:30pm, Wednesday, 14'th Aug 2024
Preliminary safety and efficacy with sustained objective responses observed in patients with lymphoma treated with MT-601 in Phase 1 APOLLO study
Marker Therapeutics to receive non-dilutive funding from NIH Small Business Innovation Research Program based on preliminary clinical results and non-clinical data in lymphoma Marker Therapeutics to r
